Search Results - "Nosenzo, M A"

  • Showing 1 - 8 results of 8
Refine Results
  1. 1

    Single-agent epirubicin as primary chemotherapy in T2-T3, N0-N2, M0 breast carcinoma: 6-year follow-up by Barni, S, Piazza, E, Frontini, L, Visini, M, Ardizzoia, A, Grassi, M M, Nosenzo, M A, Mandalà, M, Biasioli, R, Freddi, E, Lucani, L, Recalcati, A, Pravettoni, A, Sala, R, Rezzani, C, Villa, S, Trabucchi, E

    Published in Oncology (01-01-2004)
    “…Single-agent epirubicin was tested as primary chemotherapy treatment in patients with early breast cancer >3 cm. 100 women with locally advanced breast cancer…”
    Get more information
    Journal Article
  2. 2

    5-Year Results of Cisplatin-Epirubicin-Vinorelbine (PEV) Combination as Primary Chemotherapy in T2-3, N0-2 Breast Cancer Patients: A Multicentre Phase II Study by Barni, S, Visini, M, Piazza, E, Ionta, M T, Ardizzoia, A, Arnoldi, E, Fava, S, Pinotti, G, Torretta, F, Corradini, G, Villa, S, Nosenzo, A M, Massidda, B, Cazzaniga, M E

    Published in Anticancer research (01-07-2007)
    “…The aim this study was to assess the efficacy of cisplatin-epirubicin-vinorelbine, as primary chemotherapy, in reducing the tumour burden in T 2-3 N 0-2 breast…”
    Get full text
    Journal Article
  3. 3

    Vacuum-assisted breast biopsy for diagnosis of non-palpable lesions: experience with 226 cases by Nebuloni, M, Amadori, R, Antonacci, C, Rossi, R S, Sartani, A, De Simone, A, Corsi, F, Bianco, R, Nosenzo, M A, Trabucchi, E, Vago, G

    Published in Pathologica (01-06-2008)
    “…Vacuum-assisted breast biopsy (VABB) is now available for non-palpable lesions. The present study describes the results obtained from 226 consecutive VABBs…”
    Get more information
    Journal Article
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8

    The patient's point of view. Results of the Working Group on Socio-Psychological Implications of Follow-up

    Published in Annals of oncology (1995)
    “…AIM OF THE STUDY GROUP FOR PSYCHO-SOCIAL IMPLICATIONS OF FOLLOW-UP: For the first time in Italy, patients and members of breast-cancer patients' associations…”
    Get more information
    Journal Article